Drug conjugate plus immunotherapy delays advanced triple-negative breast cancer

Replacing standard chemotherapy with the antibody-drug conjugate sacituzumab govitecan, alongside the immunotherapy pembrolizumab, delayed the progression of previously untreated advanced triple-negative breast cancer: in the phase 3 ASCENT-04/KEYNOTE-D19 trial, median progression-free survival was 11.2 months with the conjugate pair against 7.8 months with chemotherapy plus pembrolizumab [s1]. The regimen also produced longer-lasting responses, but overall-survival data were still immature at this analysis, so whether patients live longer is not yet answered [s1].

The trial addresses the hardest common subtype of breast cancer. Triple-negative disease lacks the three receptors that most breast-cancer drugs target, which has long left chemotherapy as the backbone of treatment [s1]. For tumours that carry the immune marker PD-L1, adding pembrolizumab to chemotherapy is already standard first-line care; ASCENT-04 asked whether swapping the chemotherapy for sacituzumab govitecan — an antibody that carries a chemotherapy payload directly to cancer cells expressing the protein Trop-2 — does better [s1].

What they did

ASCENT-04 was an open-label, international phase 3 trial that randomly assigned 443 patients with previously untreated, PD-L1-positive, locally advanced unresectable or metastatic triple-negative breast cancer in a 1:1 ratio: 221 to sacituzumab govitecan plus pembrolizumab and 222 to the investigator's choice of chemotherapy plus pembrolizumab [s1]. Enrolment was restricted to tumours that tested positive for PD-L1, and the trial was registered and run at sites across several continents [s2]. The primary endpoint was progression-free survival judged by blinded independent central review — reviewers who did not know which treatment a patient received — with overall survival, objective response (a complete or partial shrinkage of the tumour) and duration of response among the secondary endpoints [s1].

What it showed

Median progression-free survival was 11.2 months (95% confidence interval, 9.3 to 16.7) with sacituzumab govitecan plus pembrolizumab and 7.8 months (95% confidence interval, 7.3 to 9.3) with chemotherapy plus pembrolizumab, a hazard ratio for progression or death of 0.65 (95% confidence interval, 0.51 to 0.84; two-sided P<0.001) [s1]. A hazard ratio of 0.65 means the rate of progression or death was about a third lower with the conjugate pair over the period studied. The share of patients whose tumours shrank was similar — 60% (95% confidence interval, 53 to 66) versus 53% (95% confidence interval, 46 to 60) — but among those who responded, the benefit lasted markedly longer: a median duration of response of 16.5 months against 9.2 months [s1].

The catch is the endpoint that matters most. Data on overall survival were immature, meaning too few deaths had occurred to judge whether the regimen extends life [s1]. Progression-free survival — time without the cancer growing — is a real benefit to patients, but it does not always translate into longer survival, a recurring caution in advanced breast-cancer trials that read out on tumour biology before survival. The response-duration gap is encouraging on that front, but it is not the same as a survival result.

The cost side

Serious side effects were common in both groups and near-identical in frequency: adverse events of grade 3 or higher occurred in 71% of patients on sacituzumab govitecan plus pembrolizumab and 70% of those on chemotherapy plus pembrolizumab [s1]. Where the groups diverged was in tolerability over time — discontinuation because of adverse events occurred in 12% of the conjugate group and 31% of the chemotherapy group [s1]. Adverse events leading to death occurred in 3% of patients in each group [s1]. Sacituzumab govitecan carries recognised risks of low white-cell counts and diarrhoea, so the lower dropout rate reflects a different, not absent, burden of toxicity. That the two arms shared a near-identical rate of grade 3-or-higher events, yet differed so widely in how often patients stopped treatment, suggests the conjugate's side effects were more often manageable without abandoning the drug — a distinction that matters in a disease where staying on an effective treatment is itself part of the benefit [s1].

What to watch

The trial was funded by Gilead Sciences, the drug's manufacturer, and was open-label, so patients and treating doctors knew the assignment — though the central review of progression was blinded [s1]. The result applies specifically to the PD-L1-positive group, roughly the same population for whom chemotherapy plus pembrolizumab is already used, and not to PD-L1-negative disease [s1]. It also speaks only to first-line use, not to sacituzumab govitecan given later in the disease course, where the drug is already established [s1]. The open question is survival: if the overall-survival curves eventually separate, the case for replacing chemotherapy in the first line strengthens considerably; if they do not, the choice becomes a trade between a longer progression-free interval and the specific side effects of each option. That distinction matters more here than in early-stage disease, where regimens such as atezolizumab added to chemotherapy before surgery are given with curative intent rather than to control metastatic disease.